Gene edit­ing ex­pert Char­lie Al­bright tells us why he hopped from Ed­i­tas to a new role as CSO of an up­start biotech out to en­gi­neer gene ther­a­py 2.0

We now know where Char­lie Al­bright was head­ed when he jumped ship at CRISPR gene edit­ing pi­o­neer Ed­i­tas a few weeks ago.

Al­bright has skipped across town to Waltham, MA-based Affinia, the new­ly hatched gene ther­a­py biotech — from AveX­is vets Sean Nolan and Rick Mo­di — look­ing to de­vel­op next-gen AAV de­liv­ery ve­hi­cles for a new wave of once-and-done ther­a­pies. And he’s been joined on the team by Pe­tra Kauf­mann, a vet from No­var­tis Gene Ther­a­pies — un­til re­cent­ly known as AveX­is.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER